文献速递乳腺癌

Atirmociclib联合氟维司群治疗CDK4/6抑制剂经治HR+/HER2-晚期乳腺癌:FourLight-1随机试验主要分析

Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.
PubMed 文献 · Ann Oncol · 2026-10-24

FourLight-1是一项开放标签2期随机研究,纳入263例既往辅助或一线CDK4/6抑制剂治疗进展的HR+/HER2-晚期/转移性乳腺癌患者,1:1随机接受Atirmociclib联合氟维司群或研究者选择治疗。主要终点研究者评估PFS显著改善(分层HR 0.60,95%CI 0.440-0.825,单侧P=0.0007;中位9.4 vs 6.6个月),安全性可控。

要点

  • Atirmociclib联合氟维司群较研究者选择治疗显著延长PFS(中位9.4 vs 6.6个月)。
  • 基线可测量病灶患者ORR 19.3% vs 11.3%,中位DOR 14.8 vs 9.3个月,CBR 61.9% vs 46.0%。
  • 常见任何级别TEAE为中性粒细胞减少(47.2%)、白细胞减少(33.6%)和腹泻(28.0%),6.4%因TEAE停用Atirmociclib。

核心结论

  • Atirmociclib联合氟维司群在既往CDK4/6抑制剂治疗进展的HR+/HER2-晚期/转移性乳腺癌患者中显示出显著且具有临床意义的PFS改善,安全性及耐受性可控。

研究设计与样本

  • FourLight-1为开放标签、随机2期研究,患者按1:1随机接受Atirmociclib(300 mg口服,每日两次,连续给药)联合氟维司群或研究者选择治疗(氟维司群单药或依维莫司联合依西美坦)。
  • 共纳入263例既往辅助或一线CDK4/6抑制剂治疗进展的HR+/HER2-晚期/转移性乳腺癌患者(Atirmociclib组n=126,研究者选择治疗组n=137;中位年龄57岁)。
  • 主要终点为研究者评估的无进展生存期(PFS),次要终点包括总生存期(OS)、客观缓解率(ORR)、缓解持续时间(DOR)、临床获益率(CBR)和安全性。

主要发现

  • 截至2026年1月12日数据截止,Atirmociclib组较研究者选择治疗组显著改善PFS(分层风险比0.60;95%CI 0.440-0.825;单侧P=0.0007;中位PFS 9.4 vs 6.6个月)。
  • 大多数亚组中观察到一致的PFS获益。
  • 基线可测量病灶患者中,Atirmociclib组ORR为19.3%(21例),研究者选择治疗组为11.3%(13例)(名义双侧P=0.0901);中位DOR分别为14.8个月和9.3个月;CBR分别为61.9%和46.0%。
  • Atirmociclib组最常见的任何级别治疗中出现的不良事件(TEAE)为中性粒细胞减少(47.2%)、白细胞减少(33.6%)和腹泻(28.0%);6.4%的患者因TEAE停用Atirmociclib。

临床怎么用

  • 对于既往CDK4/6抑制剂治疗进展的HR+/HER2-晚期/转移性乳腺癌患者,Atirmociclib联合氟维司群可作为潜在治疗选择,需关注中性粒细胞减少、白细胞减少和腹泻等不良事件。

局限性

  • FourLight-1为2期开放标签研究,样本量有限(263例),OS数据尚未成熟,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atirmociclib is a potential first-in-class, highly selective cyclin-dependent kinase (CDK) 4 inhibitor, demonstrating significantly greater selectivity over CDK6. In a phase 1/2a study, atirmociclib plus endocrine therapy was well tolerated and showed encouraging antitumor activity in patients with HR+/HER2- advanced/metastatic breast cancer (mBC). We present results from a randomized study of atirmociclib plus fulvestrant versus investigator's choice of therapy (ICT) in patients with HR+/HER2- mBC whose disease progressed on prior adjuvant or first-line CDK4/6 inhibitor treatment. PATIENTS AND METHODS: FourLight-1 is an open-label, phase 2 study. Patients were randomized 1:1 to atirmociclib (300 mg orally, twice daily, continuously) plus fulvestrant or ICT (fulvestrant alone or everolimus plus exemestane). The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), clinical benefit rate (CBR), and safety. RESULTS: At the data cutoff (12 January 2026), 263 patients were enrolled (atirmociclib, n = 126; ICT, n = 137; median age: 57 years). PFS was significantly improved with atirmociclib versus ICT (stratified hazard ratio: 0.60; 95% CI, 0.440-0.825; 1-sided P = 0.0007; median: 9.4 vs 6.6 months). A consistent PFS benefit was observed across most subgroups. Patients with baseline measurable disease in the atirmociclib arm had a higher ORR versus the ICT arm (21 [19.3%] vs 13 [11.3%]; nominal 2-sided P = 0.0901) and median DOR was numerically longer (14.8 vs 9.3 months, respectively); CBR was 61.9% versus 46.0%, respectively. The most common any-grade treatment-emergent adverse events (TEAEs) in the atirmociclib arm were neutropenia (47.2%), leukopenia (33.6%), and diarrhea (28.0%); 6.4% of patients discontinued atirmociclib due to TEAEs. CONCLUSIONS: Atirmociclib plus fulvestrant showed significant and clinically meaningful PFS improvement in patients who progressed on prior CDK4/6 inhibitor treatment with a manageable safety and tolerability profile.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Giordano A, Xu B, Yoshinami T, et al. Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial. Ann Oncol. 2026. PMID: 42926110. doi:10.1016/j.annonc.2026.10.1282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。